中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (8): 589-592.doi: 10.12144/zgmfskin202608589

• 病例报告 • 上一篇    下一篇

夫那奇珠单抗治疗甲银屑病一例

王娜1,2,刘永霞1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2026-08-15 发布日期:2026-08-03

Vunakizumab in the treatment of nail psoriasis: a case report

WANG Na1,2, LIU Yongxia1,2   

  1. 1 Dermatology Hospital of Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2026-08-15 Published:2026-08-03

PDF (PC)

35

摘要： 生物制剂为甲银屑病的治疗提供了新的选择，如抗TNF-α抑制剂、抗IL-17抑制剂及抗IL-12/23抑制剂等，均显示出良好的远期效果。夫那奇珠单抗作为国产新型抗 IL-17A单克隆抗体，主要用于治疗中重度斑块状银屑病，其治疗甲银屑病的临床报道较少。本文报道1例多指甲受累的甲银屑病患者，排除禁忌后予夫那奇珠单抗治疗，2个月初见疗效，6个月指甲恢复正常。

关键词: 甲银屑病, 夫那奇珠单抗, IL-17A抑制剂

Abstract: Biological agents have provided new therapeutic options for nail psoriasis. Among them, anti-TNF-α inhibitors, anti-IL-17 inhibitors, and anti-IL-12/23 inhibitors have all demonstrated favorable long-term efficacy. As a novel domestic anti-IL-17A monoclonal antibody, fonakizumab is mainly indicated for moderate-to-severe plaque psoriasis, with limited clinical reports on its use in nail psoriasis. Herein, we report a case of multi-nail involved nail psoriasis. After exclusion of contraindications, the patient was treated with fonakizumab. Clinical efficacy was observed at 2 months, and complete nail recovery was achieved at the 6-month follow-up.

Key words: nail psoriasis, vunakizumab, IL-17A inhibitor